<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03240328</url>
  </required_header>
  <id_info>
    <org_study_id>20170407V3</org_study_id>
    <nct_id>NCT03240328</nct_id>
  </id_info>
  <brief_title>The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function</brief_title>
  <official_title>The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV&#xD;
      has been successfully suppressed after cART, which is expected to enhance the&#xD;
      res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the advent of combined antiretroviral therapy (cART), the persistence of viral&#xD;
      reservoirs remains a major barrier to curing human immunodeficiency virus type 1 (HIV-1)&#xD;
      infection. Recently, the shock and kill strategy, by which HIV-1 reservoirs could be&#xD;
      eradicated following reactivation of latent HIV-1 by latency-reversing agents (LRAs), has&#xD;
      been extensively practiced. It is important to reestablish virus-specific and reliable immune&#xD;
      surveillance to eradicate the reactivated virus-harboring cells.the VC-CAR-T cells&#xD;
      effectively induced the cytolysis of LRA-reactivated HIV-1-infected CD4 T lymphocytes&#xD;
      isolated from infected individuals receiving successful cART. Our previous study demonstrated&#xD;
      that the special features of genetically engineered CAR-T cells make them a particularly&#xD;
      suitable candidate for therapeutic application in efforts to reach a functional HIV cure. In&#xD;
      this clinical trial, we intend to study the safety and effectiveness of CAR-T Cell Therapy on&#xD;
      HIV patients whose plasma HIV has been successfully suppressed after cART, by observing the&#xD;
      adverse events, HIV-1 reservoir and the immune index.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>No control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-associated adverse events of CAR-T cell therapy</measure>
    <time_frame>6 Months</time_frame>
    <description>To observe the adverse events of VC-CAR-T cell therapy on HIV-infected patients during the clinical trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 reservoir</measure>
    <time_frame>6 Months</time_frame>
    <description>To assay the HIV loads in the peripheral blood Mono-nuclear cells and plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load rebound time</measure>
    <time_frame>6 months</time_frame>
    <description>To assay the HIV viral load rebound period after discontinuing cART</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV-specific immunity</measure>
    <time_frame>6 Months</time_frame>
    <description>To assay the remaining concentration of VC-CAR-T cells in patients, the number of HIV-specific CD4,CD8 and their activity after receiving CAR-T cell therapy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>CAR-T therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA &lt;50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cells</intervention_name>
    <description>HIV-1 specific chimeric antigen receptor cells</description>
    <arm_group_label>CAR-T therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV infection confirmed.&#xD;
&#xD;
          2. Receiving cART more than 12 months.&#xD;
&#xD;
          3. HIV viral-load &lt; 50 copies/ml and CD4 cell count more than 350 cells/ul.&#xD;
&#xD;
          4. Without serious liver, heart, liver and kidney diseases.&#xD;
&#xD;
          5. The subjects know about the study and volunteer to attend the research and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With active HBV or HCV infection, or serious opportunistic infections.&#xD;
&#xD;
          2. With serious chronic disease such like diabetes, the mental illness,et al&#xD;
&#xD;
          3. History of suffering from pancreatitis during cART.&#xD;
&#xD;
          4. Pregnant or breast-fed.&#xD;
&#xD;
          5. With poor adherence.&#xD;
&#xD;
          6. Unable to complete follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cai Weiping, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou 8th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Linghua, Doctor</last_name>
    <phone>020-83710825</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai Weiping, Bachelor</last_name>
    <phone>020-83710816</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua LI, doctor</last_name>
      <phone>020-83710825</phone>
      <email>llheliza@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25. Erratum In: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>23527958</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.</citation>
    <PMID>22160384</PMID>
  </reference>
  <reference>
    <citation>Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.</citation>
    <PMID>25319501</PMID>
  </reference>
  <reference>
    <citation>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016 Mar 10;374(10):998. doi: 10.1056/NEJMx160005. No abstract available.</citation>
    <PMID>26962747</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N Engl J Med. 2011 Nov 17;365(20):1937-8; author reply 1938. doi: 10.1056/NEJMc1111004. No abstract available.</citation>
    <PMID>22087695</PMID>
  </reference>
  <reference>
    <citation>Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991 Mar 8;64(5):1037-46. doi: 10.1016/0092-8674(91)90327-u.</citation>
    <PMID>1900456</PMID>
  </reference>
  <reference>
    <citation>Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013 Nov;446(1-2):268-75. doi: 10.1016/j.virol.2013.08.002. Epub 2013 Sep 6.</citation>
    <PMID>24074590</PMID>
  </reference>
  <reference>
    <citation>Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014 Apr;32(4):1021-31. doi: 10.1002/stem.1611.</citation>
    <PMID>24307574</PMID>
  </reference>
  <reference>
    <citation>MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol. 2014 Oct;43(5):341-8. doi: 10.1111/jmp.12137. Epub 2014 Aug 20.</citation>
    <PMID>25138734</PMID>
  </reference>
  <reference>
    <citation>Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther. 2015 Aug;23(8):1358-1367. doi: 10.1038/mt.2015.102. Epub 2015 Jun 8.</citation>
    <PMID>26050990</PMID>
  </reference>
  <reference>
    <citation>Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.</citation>
    <PMID>25878112</PMID>
  </reference>
  <reference>
    <citation>Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131.</citation>
    <PMID>24329793</PMID>
  </reference>
  <results_reference>
    <citation>Liu B, Zou F, Lu L, Chen C, He D, Zhang X, Tang X, Liu C, Li L, Zhang H. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. J Virol. 2016 Oct 14;90(21):9712-9724. doi: 10.1128/JVI.00852-16. Print 2016 Nov 1.</citation>
    <PMID>27535056</PMID>
  </results_reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>September 13, 2022</last_update_submitted>
  <last_update_submitted_qc>September 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>CAR-T HIV therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>function cure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03240328
org study id: 20170407V3
nct id: NCT03240328
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV
      has been successfully suppressed after cART, which is expected to enhance the
      res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Despite the advent of combined antiretroviral therapy (cART), the persistence of viral
      reservoirs remains a major barrier to curing human immunodeficiency virus type 1 (HIV-1)
      infection. Recently, the shock and kill strategy, by which HIV-1 reservoirs could be
      eradicated following reactivation of latent HIV-1 by latency-reversing agents (LRAs), has
      been extensively practiced. It is important to reestablish virus-specific and reliable immune
      surveillance to eradicate the reactivated virus-harboring cells.the VC-CAR-T cells
      effectively induced the cytolysis of LRA-reactivated HIV-1-infected CD4 T lymphocytes
      isolated from infected individuals receiving successful cART. Our previous study demonstrated
      that the special features of genetically engineered CAR-T cells make them a particularly
      suitable candidate for therapeutic application in efforts to reach a functional HIV cure. In
      this clinical trial, we intend to study the safety and effectiveness of CAR-T Cell Therapy on
      HIV patients whose plasma HIV has been successfully suppressed after cART, by observing the
      adverse events, HIV-1 reservoir and the immune index.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: No control.
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of treatment-associated adverse events of CAR-T cell therapy
time frame: 6 Months
description: To observe the adverse events of VC-CAR-T cell therapy on HIV-infected patients during the clinical trial
measure: HIV-1 reservoir
time frame: 6 Months
description: To assay the HIV loads in the peripheral blood Mono-nuclear cells and plasma
measure: HIV viral load rebound time
time frame: 6 months
description: To assay the HIV viral load rebound period after discontinuing cART
measure: HIV-specific immunity
time frame: 6 Months
description: To assay the remaining concentration of VC-CAR-T cells in patients, the number of HIV-specific CD4,CD8 and their activity after receiving CAR-T cell therapy
arm group label: CAR-T therapy
arm group type: Experimental
description: Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
intervention type: Biological
intervention name: CAR-T cells
description: HIV-1 specific chimeric antigen receptor cells
arm group label: CAR-T therapy
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: Cai Weiping, Bachelor
role: Principal Investigator
affiliation: Guangzhou 8th People's Hospital
last name: Li Linghua, Doctor
phone: 020-83710825
email: llheliza@126.com
last name: Cai Weiping, Bachelor
phone: 020-83710816
email: gz8hcwp@126.com
facility: 
status: Recruiting
contact: 
country: China
citation: Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25. Erratum In: N Engl J Med. 2016 Mar 10;374(10):998.
PMID: 23527958
citation: Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
PMID: 22160384
citation: Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.
PMID: 25319501
citation: Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016 Mar 10;374(10):998. doi: 10.1056/NEJMx160005. No abstract available.
PMID: 26962747
citation: Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N Engl J Med. 2011 Nov 17;365(20):1937-8; author reply 1938. doi: 10.1056/NEJMc1111004. No abstract available.
PMID: 22087695
citation: Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991 Mar 8;64(5):1037-46. doi: 10.1016/0092-8674(91)90327-u.
PMID: 1900456
citation: Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013 Nov;446(1-2):268-75. doi: 10.1016/j.virol.2013.08.002. Epub 2013 Sep 6.
PMID: 24074590
citation: Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014 Apr;32(4):1021-31. doi: 10.1002/stem.1611.
PMID: 24307574
citation: MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol. 2014 Oct;43(5):341-8. doi: 10.1111/jmp.12137. Epub 2014 Aug 20.
PMID: 25138734
citation: Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther. 2015 Aug;23(8):1358-1367. doi: 10.1038/mt.2015.102. Epub 2015 Jun 8.
PMID: 26050990
citation: Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.
PMID: 25878112
citation: Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131.
PMID: 24329793
citation: Liu B, Zou F, Lu L, Chen C, He D, Zhang X, Tang X, Liu C, Li L, Zhang H. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. J Virol. 2016 Oct 14;90(21):9712-9724. doi: 10.1128/JVI.00852-16. Print 2016 Nov 1.
PMID: 27535056
responsible party type: Principal Investigator
investigator affiliation: Guangzhou 8th People's Hospital
investigator full name: Linghua LI
investigator title: Vice Chief physician
mesh term: Acquired Immunodeficiency Syndrome
mesh term: HIV Infections
sharing ipd: No